Last year, the healthcare system faced a surge of COVID, influenza, and RSV cases, filling hospitals with children in critical condition. Despite the introduction of a promising new RSV treatment, nirsevimab, its rollout was hampered by supply shortages and logistical challenges. Daniel Dodson, MD, MS, a pediatric infectious disease specialist, explained that the limited supply required careful allocation to high-risk infants, leading to difficult decisions and impassioned pleas from caregivers.Resources:Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals - Pediatric Pandemic NetworkNirsevimab Frequently Asked Questions - American Academy of PediatricsNirsevimab for Prevention of RSV in Healthy Late -Preterm and Term Infants - The New England Journal of MedicineImmunizations to Protect Infants - CDC

Ver todos los episodios